<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only with the bitherapy ledipasvir/sofosbuvir, onset of bradycardia, possibly abruptly, which can have fatal consequences.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the ledipasvir when the proton pump inhibitor is administered before the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the proton pump inhibitor and the ledipasvir be administered simultaneously </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rosuvastatin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG2>
<DESCRIPTION>When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially of the renal function</COMMENT>
</INTERACTION>
</INTERACTIONS>
